The novel agent molgramostim improved pulmonary gas exchange in autoimmune pulmonary alveolar proteinosis, a randomized trial showed. In this rare condition, surfactant builds up in the alveoli as ...
Recently these monocyte-derived alveolar macrophages, or Mo-AMs, were identified as key drivers of lung fibrosis disease progression. However, the mechanisms of their pro-fibrotic behavior and ...
You have millions of air sacs (alveoli) in your lungs. These air sacs move oxygen into your blood. Alveolar walls contain surfactant. This is a substance made of fats, proteins, and other substances.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
The aim of this study was to determine whether morphine depresses the ventilatory responses elicited by a hypoxic challenge (10% O 2, 90% N 2) in conscious rats at a time when the effects of morphine ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, ...
-- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease Burden, Restored Patient ...
When people check in for their annual mammogram these days, some may face a surprising question: In addition to reviewing the mammogram for breast cancer, would you like the radiologist to examine it ...
Venous ulcers usually occur on the legs due to blood circulation problems that damage your veins. Treatments are available to manage symptoms, help ulcers heal more quickly, or prevent them. Venous ...
The inaugural MED-TED teaching competition saw seven contestants compete against each other to teach a topic in under eight minutes. This innovative session included attending hospitalists with fewer ...
Savara Inc. is a biotech company focused on rare lung diseases that joined the Nasdaq in 2017. Today, management shared the news that lead candidate, molgramostim met primary and secondary endpoints ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback